Stem Cell Based Therapy Option in COVID-19: Is It Really Promising?

Irmak Duygu Koyuncu, Darıcı Hakan, Karaöz Erdal

Table 4 The Parallel Controlled Design along with their development phases, participant size blinding status and the treatment intervention types to cure SARS-CoV infection in ICTP database of WHO.

Protocol design: Selected Trials with Parallel Controlled Design Trial ID Phase Total target Participants Intervention ChiCTR2000029990 Phase 1-2 120 Subjects Experimental group: mesenchymal stem cells. Control group: saline. Note: Randomly divided into group A as placebo group and group B as stem cell treatment group ChiCTR2000031494 Phase 1 36 Subjects Experimental group: Conventional medication + Infusion of mesenchymal stem cells; Control group: Conventional medication. ChiCTR2000031430 Phase 2 200 Subjects Experimental group: Conventional treatment regimen + MSC treatment; Control group: Conventional treatment regimen.